N H Andrew1, D Kearney, D Selva. 1. South Australian Institute of Ophthalmology and the Department of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, South Australia. nick.h.andrew@gmail.com
Abstract
PURPOSE: The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD: Retrospective, single-centre, interventional case series. RESULTS: Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION: Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.
PURPOSE: The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH). PATIENTS AND METHOD: Retrospective, single-centre, interventional case series. RESULTS: Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection. CONCLUSION: Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.
Authors: Dipti Talaulikar; David Tridgell; David Leong; Jane E Dahlstrom; Maya Cherian; Ian Prosser; Ken Sunderland Journal: Clin Exp Ophthalmol Date: 2010-12 Impact factor: 4.207